<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028886</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069144</org_study_id>
    <secondary_id>CKTO-2001-02</secondary_id>
    <secondary_id>HOVON-50MM</secondary_id>
    <secondary_id>EU-20133</secondary_id>
    <secondary_id>HOVON-CKVO-2001-02</secondary_id>
    <nct_id>NCT00028886</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Commissie Voor Klinisch Toegepast Onderzoek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Thalidomide may stop the growth of cancer cells by stopping
      blood flow to the cancer. Peripheral blood stem cell transplant using stem cells from the
      patient or a donor may be able to replace immune cells that were destroyed by chemotherapy
      used to kill cancer cells. The donated stem cells may also help destroy any remaining cancer
      cells (graft-versus-tumor effect). It is not yet known whether chemotherapy followed by
      peripheral blood stem cell transplant is more effective with or without thalidomide in
      treating multiple myeloma.

      PURPOSE: This randomized phase III trial is studying giving combination chemotherapy with
      thalidomide to see how well it works compared with giving combination chemotherapy without
      thalidomide in treating patients with multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of doxorubicin, dexamethasone, and high-dose melphalan with versus
           without thalidomide, in terms of event-free survival, of patients with multiple myeloma.

        -  Determine the response rate, complete response rate, overall survival, and
           progression-free survival of patients treated with these regimens.

        -  Determine the safety and toxicity of thalidomide in combination with intensive
           chemotherapy in these patients.

        -  Assess the value of prognostic factors at diagnosis in individual patients treated with
           these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      participating center and treatment policy (1 course vs 2 courses of high-dose melphalan).
      Patients are randomized to 1 of 2 treatment arms.

      Arm I:

        -  Patients receive induction chemotherapy (AD) comprising doxorubicin IV on days 1-4 and
           oral dexamethasone on days 1-4, 9-12, and 17-20. Patients receive oral thalidomide daily
           beginning on day 1 and continuing until 2 weeks before start of stem cell mobilization.
           Treatment repeats every 28 days for 3 courses in the absence of disease progression or
           unacceptable toxicity.

        -  Patients receive stem cell mobilization with chemotherapy comprising cyclophosphamide IV
           on day 1 and doxorubicin IV and oral dexamethasone on days 1-4 (CAD). Patients also
           receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until
           last apheresis.

        -  Beginning 8-10 weeks after stem cell collection, patients receive low-dose oral
           thalidomide daily and high-dose melphalan IV on days -3 and -2 as intensification.
           Patients undergo stem cell infusion on day 0. Patients may receive a second course of
           high-dose melphalan 2-3 months after the first course, in which case, stem cell infusion
           follows the second course of melphalan.

        -  Patients receive maintenance therapy with oral thalidomide daily until disease
           progression or after 3 months if no response.

        -  Beginning 2 months after the last course, patients with an HLA-identical sibling donor
           undergo nonmyeloablative stem cell transplantation after radiotherapy.

      Arm II:

        -  Patients receive induction chemotherapy (VAD) comprising vincristine IV and doxorubicin
           IV on days 1-4 and dexamethasone on days 1-4, 9-12, and 17-20. Treatment repeats every
           28 days for 3 courses in the absence of disease progression or unacceptable toxicity.

        -  Patients receive stem cell mobilization with CAD chemotherapy as in arm I. G-CSF is
           given as in arm I.

        -  Patients receive high-dose melphalan and undergo stem cell infusion as in arm I.

        -  Patients receive maintenance therapy with interferon alfa SC 3 times weekly until
           progression or after 3 months if no partial response.

        -  Beginning 2 months after the last course, patients with an HLA-identical sibling donor
           undergo nonmyeloablative stem cell transplantation after radiotherapy.

      All patients are followed every 6 months for 3 years and then annually thereafter.

      PROJECTED ACCRUAL: A total of 450 patients (225 per treatment arm) will be accrued for this
      study within 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2001</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial response and complete response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed multiple myeloma

               -  Stage II or III

          -  No systemic amyloid light-chain amyloidosis

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 65

        Performance status:

          -  WHO 0-3

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  No significant hepatic dysfunction*

          -  Bilirubin less than 1.75 mg/dL*

          -  AST/ALT less than 2.5 times normal* NOTE: *Unless related to myeloma

        Renal:

          -  Not specified

        Cardiovascular:

          -  No severe cardiac dysfunction

          -  No New York Heart Association class II, III, or IV heart disease

        Other:

          -  HIV negative

          -  No active uncontrolled infection

          -  No other malignancy within the past 5 years except basal cell skin cancer or carcinoma
             in situ of the cervix

          -  No known intolerance to thalidomide

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Patients 18 to 55 years of age must not have been allocated before study randomization
             to allogeneic stem cell transplantation with an HLA-identical sibling donor

        Chemotherapy:

          -  No more than 2 prior courses of melphalan and prednisone therapy for local myeloma
             progression

          -  No other prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Prior local radiotherapy for local myeloma progression allowed

          -  No other prior radiotherapy

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Lokhorst, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis - Locatie Leyenburg</name>
      <address>
        <city>'s-Gravenhage</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <zip>3816 CP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7500 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 EZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden - Zuid</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken - locatie Sophia</name>
      <address>
        <city>Zwolle</city>
        <zip>8000 GK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Johnson DC, Corthals S, Ramos C, Hoering A, Cocks K, Dickens NJ, Haessler J, Goldschmidt H, Child JA, Bell SE, Jackson G, Baris D, Rajkumar SV, Davies FE, Durie BG, Crowley J, Sonneveld P, Van Ness B, Morgan GJ. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood. 2008 Dec 15;112(13):4924-34. doi: 10.1182/blood-2008-02-140434. Epub 2008 Sep 19.</citation>
    <PMID>18805967</PMID>
  </reference>
  <results_reference>
    <citation>Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Janssen JJ, Zijlmans M, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood. 2012 Jun 28;119(26):6219-25; quiz 6399. doi: 10.1182/blood-2011-11-393801. Epub 2012 Mar 22.</citation>
    <PMID>22442350</PMID>
  </results_reference>
  <results_reference>
    <citation>Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010 Feb 11;115(6):1113-20. doi: 10.1182/blood-2009-05-222539. Epub 2009 Oct 30.</citation>
    <PMID>19880501</PMID>
  </results_reference>
  <results_reference>
    <citation>Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Delforge M, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H; Dutch-Belgian HOVON; German GMMG. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica. 2008 Jan;93(1):124-7. doi: 10.3324/haematol.11644. Erratum in: Haematologica. 2008 Mar;93(3):480. Verhoef, Gregor [removed]; Delforge, Michel [added]; Breitkreuz, Iris [corrected to Breitkreutz, Iris].</citation>
    <PMID>18166796</PMID>
  </results_reference>
  <results_reference>
    <citation>Lokhorst H, van der Holt B, Zweegman S, et al.: Final analysis of HOVON-50 randomized phase III study on the effect of thalidomide combined with adriamycine,dexamethasone (AD) and high dose melphalan (HDM) in patients with multiple myeloma (MM). [Abstract] Blood 112 (11): A-157, 2008.</citation>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

